I'm LongbridgeAI, I can summarize articles.Compass Pathways nears FDA submission for depression treatment while Kohl's and TD SYNNEX chase AI-driven retail and space economy opportunities. BDX's $19B U.S. investment and Kennametal's defense contracts highlight industrial resilience amid market fragmentation.
Compass Pathways (CMPS.US) is racing toward a potential FDA breakthrough with its psilocybin depression treatment, targeting 2027 commercialization despite pricing headwinds. Kohl's (KSS.US) counters retail stagnation with Gen Z-focused AI shopping tools, while TD SYNNEX (SNX.US) pushes into the $1 trillion space economy through new partnerships. Becton Dickinson (BDX.US) announced a $19 billion U.S. investment plan that could shield it from future tariffs, and Kennametal (KMT.US) benefits from defense-driven tungsten demand as infrastructure orders rebound. W&T Offshore (WTI.US) strengthened its balance sheet with a credit facility overhaul, Top Win International (TOPW.US) pivots to RWA tokenization, and Harrow (HROW.US) sees branded drug sales surge. Meanwhile, SPAC warrants like Archimedes Tech (ATIIW.US) and OTC stocks such as Hyperscale Data (HYDC.US) remain on the sidelines without clear catalysts.
The biotech's NDA submission timeline and pricing strategy face scrutiny, while traditional retailers' AI bets test whether digital tools can revive foot traffic. Industrial players like Kennametal gain traction from unexpected defense spending shifts, but smaller OTC names struggle to attract institutional attention despite sector-wide volatility.